Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024

NEW YORK, NY, Jan 12, 2023 – (NewMediaWire) – PCG Digital — Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, is on track to deliver a safe and effective front-line treatment to a community of patients living with a rare, chronic cancer.

[Image: Soligenix, Inc.]

Cutaneous T-cell lymphoma (CTCL) is difficult to treat and remains an area of significant unmet medical need, with a very limited number of safe treatment options available. Soligenix estimates the potential worldwide market for its therapeutic, HyBryte(TM)(synthetic hypericin), to be in excess of $250 million for the treatment of CTCL.

Soligenix accomplished a number of key milestones in 2022, but difficult global market conditions meant the company was unable to achieve the stock price gains it had hoped for.

Soligenix has announced its intention to seek shareholder approval for a reverse stock split next month.

Watch the video interview

We spoke to Soligenix President and Chief Executive Officer, Dr. Christopher Schaber, to find out more.

Q: Why did you decide a reverse stock split was the best course of action for Soligenix, and why now?

A: The primary goal of a reverse stock split will be to maintain Soligenix’s Nasdaq listing. As we wait for a potential NDA approval from the FDA, and work towards the US launch of HyBryte, it is a critical time to remain a Nasdaq listed company.

A reverse stock split may also serve to increase the trading price of our common stock, making Soligenix a more attractive value proposition to a broader range of investors, including institutional investors. It also has the potential to support any future capital-raising efforts.

We were in discussions with Nasdaq during 2022 to request additional time to regain compliance and did not take pursuit of this action lightly. We waited as long as we could to ensure we had time to announce all of our key milestones during the year, most notably the submission of our new drug application (NDA) for HyBryte(TM) in the treatment of CTCL, which has a global market potential of approximately $250 million.

Q: How will remaining on the Nasdaq create opportunities for Soligenix shareholders?

A: We see significant potential upside for Soligenix’s shareholders. Increasing our trading price will, we believe, encourage new investor interest in Soligenix, potentially resulting in greater liquidity for our shareholders. Institutions are often reluctant to buy stocks with a price below a certain threshold, and a higher share price would increase Soligenix’s marketability, trading volume and liquidity of our common stock. Similarly, we may see renewed interest from analysts and brokers that typically avoid following or recommending companies with low stock prices.

Our Board of Directors has thoroughly reviewed Soligenix’s position and options and has approved the reverse stock split as being in the company’s best interests.

Q: Soligenix has indicated it is expecting to achieve some significant milestones in 2023. Can you expand on that?

A: Soligenix is expecting to achieve a number of important milestones in 2023. We are anticipating the FDA’s acceptance of our NDA for review in the first half of the year, and later in the year, the potential NDA approval in the US of HyBryte.

In Q4 2022, Soligenix was invited by the Biomedical Advanced Research and Development Authority (BARDA) to submit a full contract proposal for the development of single-vial, adjuvanted, heat stable subunit vaccines to prevent filovirus infection. We are expecting to hear from BARDA about this potential multi-year, multi-million dollar contract award for our vaccine candidates, SuVax(TM) and MarVax(TM), against Ebola and Marburg viruses.

Also, in Q4 2022, Soligenix initiated a Phase 2 clinical trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. We are excited to expand synthetic hypericin’s development into different cutaneous T-cell diseases such as psoriasis, as we execute on our long-term strategy to enhance the value of this unique compound. Psoriasis is a widespread unmet medical need, affecting as many as 7.5 million people in the U.S. and between 60 and 125 million people worldwide. We expect to report results from the study in the second half of 2023.

Q: Following FDA approval, what will be next for HyBryte?

A: Our NDA for HyBryte has been granted FDA orphan drug and fast track designations, due to its potential as a safe and effective front-line treatment for CTCL. We are anticipating potential approval in the second half of 2023 and we are targeting the first quarter of 2024 for our US launch.

Additionally, we announced in September 2022 that the FDA had awarded a $2.6 million Orphan Products Development grant for an expanded study of HyBryte(TM) in the treatment of CTCL, including in the home use setting. The home use setting is a very important growth area for us, so we are very excited that this investigator-initiated study will begin in the first half of this year.

Our goal remains to deliver an innovative first-in-class therapy to the CTCL community, and we believe we are on track to achieve this important goal.

For further information regarding Soligenix, Inc., please visit the Company’s website at, subscribe to the YouTube channel @Soligenix, and follow on LinkedIn and Twitter at Soligenix_Inc.
– YouTube:
– LinkedIn:
– Twitter:

PCG Digital
T: +1-646-863-6341

This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its client’s securities. See

Topic: Press release summary

Fast Track Special Courts under POCSO Act

Department of Justice has started a Centrally Sponsored Scheme in October 2019 for setting up of 1023 Fast Track Special Courts (FTSCs) for expeditious trial and disposal of cases related to rape and Protection of Children from Sexual Offences (POCSO) Act, in pursuance to the Criminal Law (Amendment) Act 2018. Initially, the scheme was for 1 year which has beencontinued up to 31.03.2023 at a cost of Rs.1,572.86 crore with central share of Rs.971.70 crore.733 FTSCs including 413 exclusive POCSO Courts are functional in 28 States/UTs (up to 31.10.2022).

Centrally Sponsored Scheme for setting up Fast Track Special Courts (FTSCs)is operational till 31.03.2023. FTSCs have disposed more than 1,24,000 cases till October, 2022. However, more than 1,93,000 cases are still pending in these courtsandhence, there is a need to extend the Scheme beyond March, 2023.  Accordingly, an evaluation study of the Scheme has been taken up as per the instant provisions.

Trial of cases comes under the domain of Judiciary. Lack of proper investigation, insufficient evidences and witnesses, family members, victim, turning hostile etc. are some of the reasons of less conviction under POCSO Act, as per information received from the High Courts.

This information was given by the Minister of Law and Justice, Shri Kiren Rijiju in a written reply in Rajya Sabha today.



(Release ID: 1881889)
Visitor Counter : 297

USA Track & Field Foundation and Healthy Kids Running Series Announce Partnership

 Healthy Kids Running Series is excited to announce a partnership with the USA Track & Field Foundation for the new Run For All initiative. Run For All will bring the tried and true programming into underserved communities in urban areas, the Foundation is generously providing registration for 200 inner city youth to participate in the fun and inclusive event series. This Series will focus on connecting participants in the area to nutritional information, local health resources and building community connection through active play, while removing traditional barriers to access like cost, transportation, and equipment.

Healthy Kids Running Series (HKRS) continues to advocate for children’s health and a “Get Up and Go” lifestyle by launching bi-annual five-week programs in 41 states across the U.S. for children ages 2 to 14. Beginning in March through May, children will participate in age-appropriate races and gain exposure to various avenues for maintaining overall health.

“HKRS are thrilled to be partnering with USATF Foundation. The mutual goal is to be able to provide programming for all runners,” says Tamara Conan, Vice President of Healthy Kids Running Series. “It’s a safe, healthy environment for kids to become interested in running and realize how fun being active really can be,” says Conan. “Healthy Kids is designed for children who have no background in running whatsoever. A child that has never run before or has no experience in racing, come and try this for the first time and fall in love with it. That’s the best part about it.”

“The Foundation is always looking for ways to support youth athletes and provide them opportunities to compete. USATF looks forward to being a part of this program and the access it will provide,” exclaimed USATF Foundation CEO Tom Jackovic. USATF Foundation’s mission is to support the development of emerging elite athletes, while fostering integration within the broader track & field community. To facilitate the physical, educational, social and character development of youth track & field athletes and to help prepare them to mature and succeed in adult life. To learn more about the USATF Foundation visit,

Healthy Kids Running Series impacts more than 60,000 youth runners in 300+ communities across the United States. Healthy Kids Running Series engages communities and families by providing an inclusive youth running experience, inspiring kids to believe in themselves and lead active healthy lifestyles. Learn more at

To register for a Series, visit Healthy Kids Running Series today. Every full Series participant will receive a T-Shirt and Medal. Registration for the five-week series is now open.

Contact Information:

Healthy Kids Running Series


Brand Enchanting Media

Nhandi Singleton




HKRS USATF Partnership


  • Children & Youth
  • Diet & Nutrition
  • Fitness
  • K-12 Education
  • Mental Health
  • Outdoor Sports
  • Parenting
  • Philanthropy & Non-profit
  • Running

Researchers track reason behind decline in star formation activity 8 billion years ago

Astronomers tracking star formation activity of the young Universe billions of years ago have long been intrigued by the fact that star formation in galaxies which was at its  highest about 8-10 billion years ago, had declined steadily thereafter. Searching for the reason behind this, they have found that the likely cause for the decline is that galaxies were running out of fuel.

The fuel critical to hydrogen formation is atomic hydrogen gas content of galaxies. Two studies that measured the atomic hydrogen content 9 billion years ago and 8 billion years ago, respectively, have helped them come to this conclusion.

A team of astronomers from the National Centre for Radio Astrophysics (NCRA-TIFR) in Pune, and the Raman Research Institute (RRI), Bangalore, an autonomous institute of the Department of Science and Technology, used the Giant Metrewave Radio Telescope (GMRT) to measure the atomic hydrogen gas content of galaxies 9 billion years ago. This is the earliest epoch in the universe for which there is a measurement of the atomic hydrogen content of galaxies. The new result is a crucial confirmation of the group’s earlier result, where they had measured the atomic hydrogen content of galaxies 8 billion years ago and pushes our understanding of galaxies to even earlier in the universe. The new research has been published in the 2 June 2021 issue of The Astrophysical Journal Letters.

Aditya Chowdhury, a Ph.D. student at NCRA-TIFR and the lead author of both the new study and 2020 one, said, “Our new results are for galaxies at even earlier times, but still towards the end of the epoch of maximum star-formation activity. We find that galaxies 9 billion years ago were rich in an atomic gas, with nearly three times as much mass in atomic gas as in stars. This is very different from galaxies today like the Milky Way, where the gas mass is nearly ten times smaller than the mass in stars.”

The measurement of the atomic hydrogen gas mass was done by using the GMRT to search for a spectral line in atomic hydrogen, which can only be detected with radio telescopes.

“The observations of our study were carried out around 5 years ago, before the GMRT was upgraded in 2018. We used the original receivers and electronics chain of the GMRT before its upgrade,” said Nissim Kanekar of NCRA-TIFR, a co-author of the study.

Barnali Das, another Ph.D. student of NCRA-TIFR, added, “However, we increased our sensitivity by observing for longer, with nearly 400 hours of observations generating large volume of data.”

“The star formation in these early galaxies was so intense that they would consume their atomic gas in just two billion years. And, if the galaxies could not acquire more gas, their star formation activity would decline and finally cease,” said Chowdhury. “It thus appears likely that the cause of the declining star- formation in the Universe is simply that galaxies were not able to replenish their gas reservoirs after some epoch, probably because there wasn’t enough gas available in their environments,” headed. 

“With the present result, using a completely different set of receivers and electronics, we now have two independent measurements of the atomic hydrogen gas mass in these early galaxies,” Kanekar pointed out.

K. S. Dwarakanath of RRI, who along with Shiv Sethi, were co-authors of the study, stressed, “Detecting the 21 cm signal from distant galaxies was the main original goal of the GMRT and continues to be a key science driver for building even more powerful telescopes like the Square Kilometre Array. These results are extremely important for our understanding of galaxy evolution.”

The research was funded by the Department of Atomic Energy, India, and the Department of Science and Technology, India.

Publication link:



Aditya Chowdhury ( ; 97651 15719),

Nissim Kanekar ( ; 9975077018),

Barnali Das (,

K.S. Dwarakanath (,

Shiv Sethi ( ; 94825 70297),

Yashwant Gupta ( ; 020 – 2571 9242)

C. H. Ishwara-Chandra (; 020 – 2571 9228),

J. K. Solanki (; 020 – 2571 9223).

Anil Raut: ( ; 86055 25945)

Caption: The two panels show the detected GMRT 21cm signal as a spectrum (left panel) and an image (right panel).

Caption: A GMRT antenna at night (Picture credit: Rakesh Rao)


SS/RP/ (DST Media Cell)

(Release ID: 1724108)
Visitor Counter : 1

Read this release in: